B6.Cg-B2mtm1Unc H2-Ab1b-tm1Doi Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma Tg(MMTV-neu/OT-I/OT-II)CBnel/Orl

Status

Available to order

EMMA IDEM:05777
Citation informationRRID:IMSR_EM:05777 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

 
International strain nameB6.Cg-B2mtm1Unc H2-Ab1b-tm1Doi Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma Tg(MMTV-neu/OT-I/OT-II)CBnel/Orl
Alternative nameSURE-L1/Her2-neu
Strain typeTransgenic Strains
Allele/Transgene symbolTg(MMTV-neu/OT-I/OT-II)CBnel, Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma, Tg(HLA-A/H2-D/B2M)1Bpe, H2-Ab1b-tm1Doi, B2mtm1Unc
Gene/Transgene symbolTg(MMTV-neu/OT-I/OT-II)CBnel, Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma, Tg(HLA-A/H2-D/B2M)1Bpe, H2-Ab1, B2m

Information from provider

ProviderYu Chun LONE
Provider affiliationINSERM U1014
Genetic informationHLA-A2+/+, HLA-DR1+/+, Her2-neu+/+, IAbeta°, b2m°
Phenotypic informationHLA-A2+, HLA-DR1+, Her2-neu+, IAbeta°, b2m°
Breeding historyCofounder strain: B6.FVB-Tg Her2-neu, N10 C57BL/6 Cofounder strain (SURE-L1): HLA-A2/HLA-DR1/IAbeta°/ b2m°, N6 C57BL/6
References
  • A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.;Pajot Anthony, Michel Marie-Louise, Fazilleau Nicolas, Pancré Véronique, Auriault Claude, Ojcius David M, Lemonnier François A, Lone Yu-Chun, ;2004;European journal of immunology;34;3060-9; 15468058
  • Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells.;Wall Erika M, Milne Katy, Martin Michele L, Watson Peter H, Theiss Patty, Nelson Brad H, ;2007;Cancer research;67;6442-50; 17616705
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredyes
Immunocompromisedyes

Information from EMMA

Archiving centreInstitut de Transgenose, INTRAGENE, Orléans, France
Animals used for archivinghomozygous males, homozygous females
Breeding at archiving centreHeterozygous knock-out for B2m (beta2m); homozygous knock-out for H2-Ab1 (AbetaA); transgenic for Tg(HLA-A/H2-D/B2M)1Bpe (HLAA2), Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma (HLADRA1) and Tg(MMTV-neu/OT-I/OT-II)CBnel (Her2-neu).

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

IMPC phenotypes (gene matching)
  • preweaning lethality, incomplete penetrance / IMPC
  • preweaning lethality, complete penetrance / IMPC
  • small superior vagus ganglion / IMPC
  • embryonic lethality prior to tooth bud stage / IMPC
  • abnormal skin morphology / IMPC
  • hydrometra / IMPC
  • increased circulating phosphate level / IMPC
MGI phenotypes (allele matching)
  • decreased level of surface class I molecules / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • decreased IgG level / MGI
  • abnormal pancreas morphology / MGI
  • decreased susceptibility to bacterial infection / MGI
  • increased IgM level / MGI
  • decreased susceptibility to autoimmune diabetes / MGI
  • decreased circulating serum albumin level / MGI
  • increased T-helper 1 cell number / MGI
  • abnormal interleukin level / MGI
  • abnormal tumor necrosis factor level / MGI
  • increased susceptibility to infection induced morbidity/mortality / MGI
  • absent CD8-positive, alpha-beta T cells / MGI
  • abnormal pancreatic beta cell morphology / MGI
  • abnormal T cell number / MGI
  • insulitis / MGI
MGI phenotypes (gene matching)
  • absent CD8-positive, alpha-beta T cells / MGI
  • decreased IgG level / MGI
  • decreased level of surface class I molecules / MGI
  • abnormal pancreas morphology / MGI
  • decreased susceptibility to bacterial infection / MGI
  • abnormal CD8-positive, alpha-beta cytotoxic T cell morphology / MGI
  • increased IgM level / MGI
  • insulitis / MGI
  • abnormal lateral geniculate nucleus morphology / MGI
  • decreased susceptibility to autoimmune diabetes / MGI
  • decreased susceptibility to parasitic infection / MGI
  • abnormal cytotoxic T cell physiology / MGI
  • abnormal pancreatic beta cell morphology / MGI
  • decreased circulating serum albumin level / MGI
  • hemochromatosis / MGI
  • abnormal T cell number / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • increased T-helper 1 cell number / MGI
  • increased gamma-delta T cell number / MGI
  • increased gamma-delta intraepithelial T cell number / MGI
  • increased tumor necrosis factor secretion / MGI
  • increased interleukin-3 secretion / MGI
  • decreased interleukin-4 secretion / MGI
  • abnormal interleukin level / MGI
  • abnormal tumor necrosis factor level / MGI
  • increased susceptibility to infection induced morbidity/mortality / MGI
  • abnormal immune system morphology / MGI
  • abnormal spleen morphology / MGI
  • abnormal immune system cell morphology / MGI
  • hemolytic anemia / MGI
  • postnatal growth retardation / MGI
  • abnormal immune system physiology / MGI
  • abnormal humoral immune response / MGI
  • decreased IgG level / MGI
  • decreased IgM level / MGI
  • autoimmune response / MGI
  • reduced fertility / MGI
  • premature death / MGI
  • abnormal T cell differentiation / MGI
  • no abnormal phenotype detected / MGI
  • abnormal spleen periarteriolar lymphoid sheath morphology / MGI
  • abnormal spleen marginal zone morphology / MGI
  • abnormal dendritic cell physiology / MGI
  • abnormal CD4-positive, alpha beta T cell morphology / MGI
  • abnormal T cell physiology / MGI
  • abnormal dendritic cell antigen presentation / MGI
  • abnormal B cell physiology / MGI
  • abnormal immunoglobulin level / MGI
  • increased IgM level / MGI
  • abnormal immune system organ morphology / MGI
  • increased urine protein level / MGI
  • abnormal cytokine secretion / MGI
  • abnormal artery development / MGI
  • abnormal response/metabolism to endogenous compounds / MGI
  • absent CD4-positive, alpha beta T cells / MGI
  • abnormal lymphocyte physiology / MGI
  • insulitis / MGI
  • increased anti-double stranded DNA antibody level / MGI
  • increased anti-single stranded DNA antibody level / MGI
  • increased anti-erythrocyte antigen antibody level / MGI
  • decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased susceptibility to experimental autoimmune myasthenia gravis / MGI
  • decreased regulatory T cell number / MGI
  • increased B cell number / MGI
  • decreased susceptibility to parasitic infection / MGI
  • increased susceptibility to parasitic infection / MGI
  • abnormal level of surface class II molecules / MGI
  • increased double-negative T cell number / MGI
  • decreased susceptibility to autoimmune disorder / MGI
  • cardiovascular system phenotype / MGI
  • immune system phenotype / MGI
  • abnormal CD4-positive, alpha-beta T cell physiology / MGI
  • abnormal response to transplant / MGI
  • increased CD4-positive, alpha beta T cell number / MGI
  • decreased CD4-positive, alpha beta T cell number / MGI
  • increased CD8-positive, alpha-beta T cell number / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • decreased single-positive T cell number / MGI
  • abnormal spleen B cell follicle morphology / MGI
  • absent spleen germinal center / MGI
  • decreased IgG1 level / MGI
  • decreased tumor necrosis factor secretion / MGI
  • decreased interleukin-12 secretion / MGI
  • abnormal lymph node cell ratio / MGI
  • abnormal neuron proliferation / MGI

Literature references

  • A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.;Pajot Anthony, Michel Marie-Louise, Fazilleau Nicolas, Pancré Véronique, Auriault Claude, Ojcius David M, Lemonnier François A, Lone Yu-Chun, ;2004;European journal of immunology;34;3060-9; 15468058
  • Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells.;Wall Erika M, Milne Katy, Martin Michele L, Watson Peter H, Theiss Patty, Nelson Brad H, ;2007;Cancer research;67;6442-50; 17616705

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).